Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Molibresib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 known ✓ | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 known ✓ | P25440 | 2/20 | 1.00 |
| ▸ | BRD3 known ✓ | Q15059 | 1/20 | 1.00 |
| ▸ | BRDT known ✓ | Q58F21 | 1/20 | 1.00 |
| ▸ | SMCHD1 | A6NHR9 | 1/20 | 1.00 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 1.00 |
| ▸ | AIP | O00170 | 1/20 | 1.00 |
| ▸ | AP3B1 | O00203 | 1/20 | 1.00 |
| ▸ | PSMD11 | O00231 | 1/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | SAP18 | O00422 | 1/20 | 1.00 |
| ▸ | KPNA3 | O00505 | 1/20 | 1.00 |
| ▸ | PPP6C | O00743 | 1/20 | 1.00 |
| ▸ | TCERG1 | O14776 | 1/20 | 1.00 |
| ▸ | UBE2L6 | O14933 | 1/20 | 1.00 |
| ▸ | PPP1R12A | O14974 | 1/20 | 1.00 |
| ▸ | U2SURP | O15042 | 1/20 | 1.00 |
| ▸ | SETD1A | O15047 | 1/20 | 1.00 |
| ▸ | ARPC1B | O15143 | 1/20 | 1.00 |
| ▸ | POLR1C | O15160 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Molibresib SCHEMBL12966358 | 1.00 | BRD4 (1.00) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL29359178 | 1.00 | BRD4 (1.00) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL1872390 | 1.00 | BRD4 (1.00) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL19459525 | 0.98 | BRD4 (0.97) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL19459514 | 0.96 | BRD4 (0.92) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL18260664 | 0.95 | BRD4 (0.91) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL18260675 | 0.95 | BRD4 (0.91) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL9998851 | 0.95 | BRD4 (0.91) | BRD4BRD2SMCHD1MYO1GAIP | |
| Molibresib SCHEMBL18269839 | 0.94 | BRD4 (0.89) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL15980874 | 0.94 | BRD4 (0.88) | BRD4BRD2SMCHD1MYO1GAIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043322-A1 | METHOD FOR PRODUCING TARGE VIRUSES AND CULTURE COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | claimed |
| WO-2024043322-A1 | METHOD FOR PRODUCING TARGE VIRUSES AND CULTURE COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11319326-B2 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer | JUBILANT BIOSYS LIMITED (IN) | 2022-05-03 | — | — | US | disclosed |
| WO-2021262962-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | CELGENE CORPORATION (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3347356-B1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-2968360-B1 | QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2020-10-29 | — | — | US | disclosed |
| EP-3050885-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | Glaxosmithkline LLC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2968360-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | ConverGene LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150299210-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-03 | — | — | US | disclosed |
| US-9102677-B2 | Benzodiazepine bromodomain inhibitor | GLAXOSMITHKLINE LLC (US) | 2015-08-11 | — | — | US | disclosed |
| WO-2015079259-A2 | ENZYMES FUNCTIONAL PROBES | UNIVERSITY OF DUNDEE (GB) | 2015-06-04 | — | — | WO | disclosed |
| WO-2014159837-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120252781-A1 | Benzodiazepine Bromodomain Inhibitor | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011054845-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319326-B2 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer | BRD3, BRD4, BRD2 | BRD4 2/4885BRD2 3/4885BRD3 1/4885 |
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BRD2 | BRD4 1/4885BRD2 3/4885BRD3 4/4885 |
| US-11666580-B2 | Mechanism of resistance to bet bromodomain inhibitors | BET1, BRD2, BRD4 | BRD4 3/4885BRD2 2/4885BRD3 7/4885 |
| US-20150299210-A1 | Benzodiazepine Bromodomain Inhibitor | GABRB1, GABRB3, GABRB2 | BRD4 4/4885BRD2 18/4885BRD3 11/4885 |
| US-20200368248-A1 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | BET1, BRD2, BRD4 | BRD4 3/4885BRD2 2/4885BRD3 7/4885 |
| US-20150246923-A1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885BRD2 5/4885BRD3 2/4885 |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | BRD4 4/4885BRD2 5/4885BRD3 2/4885 |
| US-20120252781-A1 | Benzodiazepine Bromodomain Inhibitor | GABRB1, GABRB3, GABRB2 | BRD4 4/4885BRD2 18/4885BRD3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.